Submit your Defective Drugs claim details for a free, no obligation case review.
Get Started:
drug_recall celebrexA Celebrex attorney is a legal professional who can help a person seek compensation for Celebrex injuries. A Celebrex attorney specializes in defective drug personal injury litigation, is familiar with the serious side effects caused by Celebrex use, and knows the laws and related information that will protect and maximize a victim’s legal interests. A Celebrex attorney can evaluate an individual’s Celebrex injury case to determine whether or not filing a Celebrex lawsuit would be in their best interest.
A Celebrex attorney can help a person determine their legal rights and options after a Celebrex related injury. Celebrex is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID) in the same class of prescription drugs as Vioxx and Bextra. Both Vioxx and Bextra were pulled from the market after studies found significant cardiovascular risks associated with these drugs. Clinical studies have found similar, if not greater, risks associated with Celebrex use, yet Celebrex remains on the market.
After researchers discovered that Celebrex use can double and triple a patient’s risk of suffering a cardiovascular injury, Pfizer announced that they would further investigate these findings but made no indication that they would recall this drug to protect consumer health. The FDA and other health agencies ordered the review of a number of Celebrex clinical trials. The FDA immediately urged doctors to reduce their prescribing of Celebrex and to look for alternative treatments. After some period of review, the FDA also ordered Pfizer to pull all Celebrex ads pending further investigation of its risks, adding that Pfizer overstated the benefits and understated the risks associated with their top selling prescription painkiller.
A Celebrex attorney can use these facts to demonstrate how Pfizer has consistently failed to inform and protect consumers from potentially deadly Celebrex risks. When a company markets a product, including drugs, they have a responsibility to inform and protect consumers from potential injuries caused by their product. When these dangers become greater than the intended benefits of the product or drug, the company has a duty to consider taking their defective product off the market. A Celebrex attorney has intimate knowledge of the laws related to product liability and drug defects and can use these to develop a strong case for a Celebrex victim.
A Celebrex attorney can also inform a Celebrex injury victim about the other legal suits that have already been brought against Pfizer for marketing this arguably defective drug. In December 2004, a Celebrex class action lawsuit was filed on behalf of all persons who have taken Celebrex in the United States. This lawsuit alleges that Pfizer negligently marketed Celebrex despite their knowledge of its serious side effects.
A Celebrex attorney can evaluate an individual’s case to explore the legal options that would best serve their interests. A Celebrex attorney can help a Celebrex injury victim seek compensation for related medical expenses, loss of income, disability, and psychological suffering, and more.
If you would like to learn more about Celebrex, you may wish to contact a Celebrex attorney who can evaluate your case.
After COX-2 painkillers – Vioxx, Celebrex and Bextra- came under scrutiny when cardiovascular risks were associated to the drugs some drugmakers saw this as an opportunity to try to capitalize on the events.
Vioxx went off the market in Se...
Merck & Co. and Pfizer Inc. have been criticized for their aggressive marketing campaigns for its COX-2 drugs, putting scrutiny on pharmaceutical advertising as a whole. Between December 2003 and November 2004, pharmaceutical ad spending increased 30...
A three-day FDA Advisory Committee meeting has wrapped, but the COX-2 drugs controversy is still not resolved. Although the panel of government medical experts advised keeping the drugs, including Pfizer Inc.’s Celebrex and Bextra, on the market, new...